Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HBB | P68871 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326261 | 0.83 | ALDH1A1 (0.65) | ALDH1A1HPGDMAPTALOX15TSHR | |
| SCHEMBL11421704 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HPGDMAPTALOX15TSHR | |
| SCHEMBL11024184 | 0.75 | ALDH1A1 (0.61) | ALDH1A1HPGDMAPTALOX15TSHR | |
| SCHEMBL24851242 | 0.74 | RAB9A (0.69) | ALDH1A1HPGDMAPTALOX15TSHR | |
| SCHEMBL2906433 | 0.71 | MEN1 (0.59) | ALDH1A1HPGDMAPTALOX15TSHR | |
| SCHEMBL608828 | 0.71 | MEN1 (0.59) | ALDH1A1HPGDMAPTALOX15TSHR | |
| SCHEMBL11044849 | 0.71 | ALDH1A1 (0.56) | ALDH1A1HPGDMAPTALOX15TSHR | |
| SCHEMBL611461 | 0.71 | ALDH1A1 (0.56) | ALDH1A1HPGDMAPTALOX15TSHR | |
| SCHEMBL23407821 | 0.71 | TSHR (0.67) | ALDH1A1HPGDMAPTALOX15TSHR | |
| SCHEMBL10001067 | 0.71 | RAB9A (0.77) | ALDH1A1HPGDMAPTALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167372-B1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO PERFUMERY CO LTD (JP) | 2003-12-10 | — | — | EP | disclosed |
| US-6455720-B1 | AS CATALYSTS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-05-16 | — | — | US | disclosed |
| EP-1167372-A1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | Takasago International Corporation (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | DDT, PDCD11, PLD2 | ALDH1A1 2369/4885HPGD 3594/4885MAPT 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.